abstract |
Disclosed are checkpoint modulator antagonists that specifically bind TIGIT, PD-1 and/or PD-L1. Also disclosed are methods of making and using the checkpoint modulator inhibitors, including monospecific, bispecific and trispecific checkpoint modulator antagonists thereof. |